Compare Adecoagro SA (AGRO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Moderna, Inc. — how do they compare? Adecoagro SA trades at $9.2 (market cap $1.36B), while Moderna, Inc. trades at $62.09 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 17.8× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| AGRO | MRNA | |
|---|---|---|
Market Cap | $1.36B | $24.18B |
Sector | Technology | Health |
52-Week High | $15.25 | $81.80 |
52-Week Low | $7.13 | $22.36 |
Enterprise Value | $3.39B | $20.33B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO is trading at $9.01, down 6.73% today, with a bearish technical outlook despite attractive valuation ratios (P/S: 0.71, P/B: 0.77). The company reported mixed quarterly results with one beat and three misses in recent quarters, while showing improved adjusted EBITDA of $172.5 million in Q2 2026. Recent expansion via the Caarapó mill acquisition and Profertil integration provides growth catalysts amid commodity volatility.
The stock presents a value opportunity with below-market multiples but faces execution risks from negative earnings momentum and high leverage. Analyst consensus is mixed with 37.5% buy ratings and a $12.12 price target, suggesting 35% upside potential if operational improvements materialize.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
